714 related articles for article (PubMed ID: 31630044)
41. Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non-small cell lung cancer.
Chang G; Li W; Bai H; Duan J; Wang Z; Du X; Yu R; Wang Y; Wang M; Zhu Y; Zhang X; Li L; Wan R; Wang J
Thorac Cancer; 2022 Nov; 13(21):2951-2959. PubMed ID: 36126963
[TBL] [Abstract][Full Text] [Related]
42. Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer.
Sakai T; Udagawa H; Matsumoto S; Yoh K; Nosaki K; Ikeda T; Zenke Y; Kirita K; Niho S; Akimoto T; Goto K; Ishii G
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1227-1237. PubMed ID: 32997195
[TBL] [Abstract][Full Text] [Related]
43. Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.
Abou-Taleb H; Yamaguchi K; Matsumura N; Murakami R; Nakai H; Higasa K; Amano Y; Abiko K; Yoshioka Y; Hamanishi J; Koshiyama M; Baba T; Yamada R; Matsuda F; Konishi I; Mandai M
Oncotarget; 2016 Aug; 7(34):54758-54770. PubMed ID: 27340867
[TBL] [Abstract][Full Text] [Related]
44. BAFfling pathologies: Alterations of BAF complexes in cancer.
Arnaud O; Le Loarer F; Tirode F
Cancer Lett; 2018 Apr; 419():266-279. PubMed ID: 29374542
[TBL] [Abstract][Full Text] [Related]
45. SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant.
Cheung AH; Wong KY; Chau SL; Xie F; Mui Z; Li GY; Li MSC; Tong J; Ng CS; Mok TS; Kang W; To KF
Pathology; 2024 Jun; 56(4):504-515. PubMed ID: 38413251
[TBL] [Abstract][Full Text] [Related]
46. Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience.
Arak H; Aytekin A; Canoz O; Ozkan M
Turk Patoloji Derg; 2021; 37(3):239-248. PubMed ID: 34514576
[TBL] [Abstract][Full Text] [Related]
47. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
48. Loss of function of SWI/SNF chromatin remodeling genes leads to genome instability of human lung cancer.
Huang HT; Chen SM; Pan LB; Yao J; Ma HT
Oncol Rep; 2015 Jan; 33(1):283-91. PubMed ID: 25370573
[TBL] [Abstract][Full Text] [Related]
49. Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma.
Yoon N; Kim J; Maeng LS; Ahn JH; Park ES
Anticancer Res; 2018 Oct; 38(10):6003-6008. PubMed ID: 30275232
[TBL] [Abstract][Full Text] [Related]
50. A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.
Kerr KM; Thunnissen E; Dafni U; Finn SP; Bubendorf L; Soltermann A; Verbeken E; Biernat W; Warth A; Marchetti A; Speel EM; Pokharel S; Quinn AM; Monkhorst K; Navarro A; Madsen LB; Radonic T; Wilson J; De Luca G; Gray SG; Cheney R; Savic S; Martorell M; Muley T; Baas P; Meldgaard P; Blackhall F; Dingemans AM; Dziadziuszko R; Vansteenkiste J; Weder W; Polydoropoulou V; Geiger T; Kammler R; Peters S; Stahel R;
Lung Cancer; 2019 May; 131():95-103. PubMed ID: 31027705
[TBL] [Abstract][Full Text] [Related]
51. Loss of switch/sucrose non-fermenting complex protein expression in undifferentiated gastrointestinal and pancreatic carcinomas.
Tessier-Cloutier B; Schaeffer DF; Bacani J; Marginean CE; Kalloger S; Köbel M; Lee CH
Histopathology; 2020 Jul; 77(1):46-54. PubMed ID: 32413172
[TBL] [Abstract][Full Text] [Related]
52. [Clinicopathological features and prognosis of SMARCA4-deficient non-small cell lung carcinoma: an analysis of 127 cases].
Li SL; Wu CY; Zhang LP; Huang Y; Wu W; Zhang W; Hou LK
Zhonghua Bing Li Xue Za Zhi; 2023 Jul; 52(7):665-670. PubMed ID: 37408395
[No Abstract] [Full Text] [Related]
53. Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
Shinno Y; Yoshida A; Masuda K; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y
Clin Lung Cancer; 2022 Jul; 23(5):386-392. PubMed ID: 35618627
[TBL] [Abstract][Full Text] [Related]
54. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.
Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ
Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315
[TBL] [Abstract][Full Text] [Related]
55. Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.
Zhou C; Che G; Zheng X; Qiu J; Xie Z; Cong Y; Pei X; Zhang H; Sun H; Ma H
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2663-2674. PubMed ID: 31541338
[TBL] [Abstract][Full Text] [Related]
56. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
[TBL] [Abstract][Full Text] [Related]
57. Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
Song Z; Cheng G; Xu C; Wang W; Shao Y; Zhang Y
Lung Cancer; 2018 Apr; 118():57-61. PubMed ID: 29572003
[TBL] [Abstract][Full Text] [Related]
58. SWI/SNF complex gene variations are associated with a higher tumor mutational burden and a better response to immune checkpoint inhibitor treatment: a pan-cancer analysis of next-generation sequencing data corresponding to 4591 cases.
Li Y; Yang X; Zhu W; Xu Y; Ma J; He C; Wang F
Cancer Cell Int; 2022 Nov; 22(1):347. PubMed ID: 36371186
[TBL] [Abstract][Full Text] [Related]
59. The clinicopathological features of BRG1-deficient non-small cell lung cancer and its response to immunotherapy: A single-center retrospective study.
Zhang J; Zhao R; Xu H; Dong L; Chen X
Ann Diagn Pathol; 2023 Dec; 67():152192. PubMed ID: 37639838
[TBL] [Abstract][Full Text] [Related]
60. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
